Hodgkin Disease
Information
- Disease name
- Hodgkin Disease
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03935282 | Active, not recruiting | N/A | Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors | October 1, 2020 | March 7, 2025 |
| NCT02927769 | Active, not recruiting | Phase 2 | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment | March 28, 2017 | November 10, 2024 |
| NCT00039676 | Active, not recruiting | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | July 8, 2002 | ||
| NCT03755414 | Active, not recruiting | Phase 1 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | September 4, 2019 | September 5, 2024 |
| NCT04459416 | Active, not recruiting | Phase 3 | Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma | June 30, 2020 | June 2025 |
| NCT02663297 | Active, not recruiting | Phase 1 | Administration of T Lymphocytes for Prevention of Relapse of Lymphomas | July 15, 2016 | January 2037 |
| NCT04998331 | Active, not recruiting | A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin | October 29, 2021 | June 30, 2024 | |
| NCT02979522 | Active, not recruiting | Phase 1/Phase 2 | A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | September 6, 2017 | September 24, 2029 |
| NCT01956084 | Active, not recruiting | Phase 1 | Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma | November 2013 | November 2025 |
| NCT01333046 | Active, not recruiting | Phase 1 | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL | January 2012 | September 27, 2027 |
| NCT00241358 | Completed | Phase 1/Phase 2 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | May 2004 | February 2010 |
| NCT00261677 | Completed | Phase 3 | A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | August 2000 | October 2003 |
| NCT00388349 | Completed | Phase 2 | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | September 2001 | September 2010 |
| NCT00398411 | Completed | Phase 3 | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells | October 2006 | December 2008 |
| NCT00444912 | Completed | Phase 2 | The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | February 2006 | June 2009 |
| NCT00478959 | Completed | Phase 2 | Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma | December 2006 | June 2014 |
| NCT00534820 | Completed | N/A | Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | June 2004 | August 2013 |
| NCT00534989 | Completed | N/A | Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT | September 2007 | December 2013 |
| NCT00540007 | Completed | Phase 2 | Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma | September 6, 2007 | September 1, 2016 |
| NCT00562224 | Completed | Phase 1 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | November 2007 | September 2010 |
| NCT00636311 | Completed | Phase 2 | A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma | February 2008 | February 2010 |
| NCT00724984 | Completed | Phase 1/Phase 2 | Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma | July 2008 | |
| NCT00733824 | Completed | Phase 1/Phase 2 | Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | November 2008 | September 2013 |
| NCT00779584 | Completed | Phase 1 | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | October 17, 2008 | May 28, 2011 |
| NCT00871702 | Completed | Phase 1 | Infusion of Genetically Modified T Cell for Post Transplant Patients With Relapsed Disease | October 2010 | November 2012 |
| NCT00901069 | Completed | Phase 1 | Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma | May 2009 | November 2012 |
| NCT00903890 | Completed | Cardiac Effects in Long-Term Survivors of Hodgkin's and Non-Hodgkin's Lymphoma | August 2008 | April 9, 2020 | |
| NCT02686346 | Completed | Phase 1/Phase 2 | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE | March 2016 | July 12, 2021 |
| NCT00026208 | Completed | Phase 2 | Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | June 2001 | February 13, 2017 |
| NCT00038558 | Completed | Phase 3 | Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy | November 2001 | March 2005 |
| NCT00039910 | Completed | Phase 3 | Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia | July 2000 | March 2003 |
| NCT00051597 | Completed | Phase 1/Phase 2 | A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies | August 2003 | |
| NCT00062868 | Completed | Phase 1 | LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma | September 2003 | April 2020 |
| NCT00113724 | Completed | Phase 1 | Study of TPI 287 in Patients With Advanced Malignancies | May 2005 | January 2008 |
| NCT00145613 | Completed | Phase 2 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | June 2003 | February 2009 |
| NCT00186251 | Completed | N/A | High Dose Chemotherapy Followed By PBSC Rescue for HD | March 1998 | July 2005 |
| NCT00196885 | Completed | Phase 2 | Effect of an Antioxidant on Cancer-Cachectic Patients Undergoing Exercise Training | December 2003 | December 2006 |
| NCT01018979 | Completed | Phase 2 | Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | February 2010 | October 2011 |
| NCT01078350 | Completed | Consent for Obtaining Additional Tissue at the Time of a Diagnostic Biopsy | May 2004 | December 4, 2015 | |
| NCT01135849 | Completed | B-Receptor Signaling in Cardiomyopathy | November 2008 | October 2010 | |
| NCT01141959 | Completed | Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients | May 2010 | December 2011 | |
| NCT01149668 | Completed | Phase 1 | A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer | June 2010 | April 2013 |
| NCT01158118 | Completed | Phase 2 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | April 1, 2011 | December 31, 2016 |
| NCT01195766 | Completed | Phase 2 | Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma | July 2010 | May 2015 |
| NCT01207921 | Completed | Phase 1 | Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma | April 28, 2011 | March 5, 2021 |
| NCT01716806 | Completed | Phase 2 | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | October 31, 2012 | September 12, 2023 |
| NCT01764230 | Completed | N/A | Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients | January 2004 | January 2008 |
| NCT01858922 | Completed | Phase 2 | Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A | December 19, 2012 | August 12, 2019 |
| NCT01874054 | Completed | Phase 1/Phase 2 | Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma | June 2013 | February 20, 2018 |
| NCT01969435 | Completed | Phase 2 | Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma | March 19, 2014 | May 31, 2017 |
| NCT02057185 | Completed | Occupational Status and Hematological Disease | September 8, 2014 | November 11, 2015 | |
| NCT02104427 | Completed | Phase 2 | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | February 2015 | November 2015 |
| NCT02181218 | Completed | Phase 1 | Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas | February 4, 2015 | June 26, 2020 |
| NCT02181738 | Completed | Phase 2 | Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational) | August 12, 2014 | December 27, 2022 |
| NCT02378337 | Completed | Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality | September 2014 | March 2016 | |
| NCT02389101 | Completed | N/A | Molecular and Whole-body MR Imaging in Lymphomas | October 2014 | September 2016 |
| NCT02567851 | Completed | Phase 2 | A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity | February 2014 | October 2, 2017 |
| NCT02639559 | Completed | Phase 2 | Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies | March 31, 2016 | April 7, 2023 |
| NCT00025662 | Completed | Phase 2 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | May 2001 | February 2008 |
| NCT02885038 | Completed | Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies | January 2015 | March 2016 | |
| NCT02939014 | Completed | Phase 2 | Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) | November 7, 2016 | February 3, 2020 |
| NCT03838627 | Completed | Feasibility and Agreement of Remote Evaluation of Resting Heart Rate and Heart Rate Variability in Survivors of Hodgkin Lymphoma Treated With Chest Radiation (PILOT STUDY-SURVIVOR) | February 5, 2019 | June 30, 2023 | |
| NCT03942263 | Completed | A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation | May 31, 2019 | December 8, 2022 | |
| NCT04629430 | Completed | N/A | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT | February 19, 2021 | October 28, 2022 |
| NCT05188755 | Completed | N/A | Fitness Assessment in Young Adults Recovered From Lymphoma | January 1, 2022 | December 6, 2022 |
| NCT06116929 | Not yet recruiting | N/A | Hodgkin's Disease and Chemotherapy Before 40 Years | May 15, 2024 | January 1, 2028 |
| NCT05544968 | Not yet recruiting | Phase 1/Phase 2 | CD30biAb-AATC for CD30+ Malignancies | December 2024 | January 2027 |
| NCT04072393 | Recruiting | N/A | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | January 15, 2021 | March 31, 2025 |
| NCT02682667 | Recruiting | Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols | April 11, 2016 | December 1, 2027 | |
| NCT06254495 | Recruiting | Phase 1 | A Safety Study of SGN-35C in Adults With Advanced Cancers | May 31, 2024 | August 31, 2028 |
| NCT04671693 | Recruiting | N/A | A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. | December 24, 2020 | April 24, 2028 |
| NCT06093334 | Recruiting | N/A | Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD | October 17, 2023 | December 2024 |
| NCT05255601 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | September 13, 2022 | July 5, 2028 |
| NCT01676805 | Recruiting | Tissue Collection for Studies of Lymph Cancer | September 21, 2012 | ||
| NCT02287311 | Recruiting | Phase 1 | Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) | February 2015 | March 2029 |
| NCT06120504 | Recruiting | Phase 1 | A Safety Study of SGN-35T in Adults With Advanced Cancers | February 29, 2024 | April 30, 2030 |
| NCT01758042 | Recruiting | N/A | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders | November 2012 | July 2027 |
| NCT03739502 | Recruiting | Phase 2 | A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant | February 28, 2019 | April 2026 |
| NCT03598608 | Recruiting | Phase 1/Phase 2 | Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) | October 17, 2018 | April 19, 2028 |
| NCT01555853 | Terminated | Phase 1 | Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | July 2012 | June 2016 |
| NCT00275262 | Terminated | Phase 2 | A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation | February 2006 | |
| NCT01745354 | Terminated | Phase 1 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | August 2012 | November 2014 |
| NCT00909948 | Terminated | Phase 1 | Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant | November 2008 | August 2012 |
| NCT00148018 | Terminated | Phase 2 | Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma | March 2005 | |
| NCT00916045 | Terminated | Phase 2 | Pilot Study of Unrelated Cord Blood Transplantation | September 2009 | March 2012 |
| NCT00058773 | Terminated | Phase 1 | Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease | January 1996 | August 2006 |
| NCT00514722 | Terminated | N/A | Pilot Study of Umbilical Cord Blood Transplantation in Adult Patient With Advanced Hematopoietic Malignancies | October 2002 | March 2009 |
| NCT01121120 | Terminated | Phase 2 | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients | June 2010 | December 2020 |
| NCT02867618 | Terminated | Phase 1/Phase 2 | Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma | October 16, 2016 | June 30, 2020 |
| NCT01188915 | Terminated | N/A | Personalised Program for Women Treated for Hodgkin Disease | July 2010 | July 2026 |
| NCT00393380 | Terminated | Phase 2 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor | September 2006 | March 2012 |
| NCT02376699 | Terminated | Phase 1 | Safety Study of SEA-CD40 in Cancer Patients | February 28, 2015 | April 14, 2023 |
| NCT01343368 | Terminated | Phase 2 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | July 2011 | April 2015 |
| NCT01468311 | Terminated | Phase 1/Phase 2 | Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma | October 11, 2011 | October 22, 2020 |
| NCT00225173 | Terminated | Phase 2 | Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease | October 2001 | September 2006 |
| NCT00538551 | Unknown status | Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases | January 2007 | July 2015 | |
| NCT02589548 | Unknown status | Brazilian Prospective Hodgkin Lymphoma Registry | October 2009 | December 2022 | |
| NCT01490957 | Unknown status | Functional Assessment of Cancer Therapy - Bone Marrow Transplant | March 2008 | ||
| NCT00188149 | Unknown status | Phase 4 | Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET | May 2000 | December 2007 |
| NCT03527628 | Unknown status | Phase 2 | OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy | January 1, 2018 | January 15, 2022 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D006689